Background: Infections cause significant treatment-related morbidity during pediatric acute lymphoblastic leukemia/lymphoma (ALL/LLy) therapy. Fevers during periods without severe neutropenia are common, but etiologies are not well-described. This study sought to describe the bloodstream infection (BSI) and non-BSI risk in children undergoing therapy for ALL/LLy.
Methods: Demographic and clinical data were abstracted for febrile episodes without severe neutropenia at two children's hospitals. Treatment courses were stratified by intensity. Multivariate logistic regression evaluated characteristics associated with infection.
Results: There were 1591 febrile episodes experienced by 524 patients. Of these, 536 (34%) episodes had ≥1 infection; BSI occurred in 30 (1.9%) episodes. No BSIs occurred in episodes with a recent procedural sedation or cytarabine exposure. Presence of hypotension, chills/rigors, higher temperature, and infant phenotype were independently associated with BSI (p < .05). Of the 572 non-BSIs, the most common was upper respiratory infection (URI) (n = 381, 67%). Compared to episodes without infection, URI symptoms, higher temperature, absolute neutrophil count 500-999/μl, and evaluation during a low-intensity treatment course were more likely to be associated with a non-BSI (p < .05) and inpatient status was less likely to be associated with a non-BSI (p < .05).
Conclusions: The BSI rate in pediatric patients with ALL/LLy and fever without severe neutropenia is low, but one-third of the time, patients have a non-BSI. Future research should test if the need for empiric antibiotics can be tailored based on the associations identified in this study.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311637 | PMC |
http://dx.doi.org/10.1002/cncr.34476 | DOI Listing |
J Int Med Res
March 2025
Infectious Diseases and Clinical Microbiology Clinic, University of Health Science Izmir Bozyaka Training and Research Hospital, Izmir, Turkey.
ObjectivesAcute leukemia often leads to severe complications such as febrile neutropenia. Mortality rates remain high, underscoring the need for novel prognostic markers. Regulatory T cells (Tregs) have not been extensively studied in this context.
View Article and Find Full Text PDFJ Clin Neurol
March 2025
Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.
Background And Purpose: Treatments for neuromyelitis optica spectrum disorder (NMOSD) such as eculizumab, ravulizumab, satralizumab, and inebilizumab have significantly advanced relapse prevention, but they remain expensive. Rituximab is an off-label yet popular alternative that offers a cost-effective solution, but its real-world efficacy needs better quantification for guiding the application of newer approved NMOSD treatments (ANTs). This study aimed to determine real-world rituximab failure rates to anticipate the demand for ANTs and aid in resource allocation.
View Article and Find Full Text PDFZhonghua Xue Ye Xue Za Zhi
January 2025
The First Affiliated Hospital of Harbin Medical University, Heilongjiang Institute of Hematology & Oncology, Harbin 150001, China.
To identify the clinical characteristics and prognosis of patients with hematological disease and neutropenic sepsis in the hematological intensive care unit (HCU). A retrospective analysis was conducted on patients with hematological disease and sepsis who admitted to HCU, the First Affiliated Hospital of Harbin Medical University from October 2017 to October 2024, to examine the primary therapeutic options, prognosis, cause of death, and infectious features of sepsis. A total of 245 septic patients were included in the study, comprising 88 cases in the neutropenic sepsis group (neutropenic group) and 157 cases in the non-neutropenic sepsis group (non-neutropenic group).
View Article and Find Full Text PDFAnn Allergy Asthma Immunol
March 2025
Division of Immunology, Allergy and Retrovirology, Department of Pediatrics. Baylor College of Medicine. Houston and The Woodlands, TX. Electronic address:
Hematopoietic stem cell transplant has been the single curative treatment for inborn errors of immunity (IEI) and is recommended for the most severe IEI conditions, such as severe combined immunodeficiency (SCID). However, adverse outcomes primarily due to histocompatibility differences between the donor and the patient are still of concern. Progress in genetic and molecular mechanisms, as well as new technology to insert DNA sequences in cell genomes has allowed the development of strategies to treat genetic diseases by correcting the gene defect in patients' cells.
View Article and Find Full Text PDFPediatr Transplant
May 2025
Department of Paediatric Gastroenterology, Hepatology and Nutrition, King's College Hospital, London, UK.
Background: Invasive fungal infections (IFI) remain a leading cause of mortality in liver transplant (LTX) patients with neutropenia. Hematopoietic growth factors and granulocyte transfusions (GTx) have been historically used in patients with neutropenia and after hematopoietic stem cell transplantation (HSCT) to treat IFI, but none thus far, in pediatric liver transplant recipients (PLTR).
Methods: We evaluated the safety and effect of GTx for life-threatening IFI, refractory to conventional antifungal treatment, in PLTR with hepatitis-associated aplastic anemia (HAAA) at King's College Hospital, London.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!